Coronavirus Disease COVID 19 News and Research

Latest Coronavirus Disease COVID 19 News and Research

Antifungal agent Bifonazole as an antiviral against SARS-CoV-2

Antifungal agent Bifonazole as an antiviral against SARS-CoV-2

In a recent study published in the journal Molecular Therapy, researchers identified Bifonazole, an imidazole-based antifungal agent, to have potent activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using high-throughput screening of small molecules.

12 May 2022

The promise of RNA medicine is targeted and personalized

The promise of RNA medicine is targeted and personalized

The development of messenger RNA (mRNA) vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has only increased the impetus in this field.

11 May 2022

Misperception of group concerns undermines cooperation and trust

Misperception of group concerns undermines cooperation and trust

Misperceptions of marginalized and disadvantaged communities' level of concern regarding COVID-19, as well as other issues such as climate change, constitutes a form of social misinformation that may undermine cooperation and trust needed to address collective problems, according to new Cornell-led research.

11 May 2022

Discovery of host co-factors necessary for SARS-CoV2 infection

Discovery of host co-factors necessary for SARS-CoV2 infection

A new study published in the journal EMBO Reports has reported on the shedding of two proteases, namely, ADAM10 and ADAM17, which aids in S protein-dependent molecular events.

11 May 2022

Unique binding property may explain the ability of delta variant to spread more rapidly

Unique binding property may explain the ability of delta variant to spread more rapidly

Unlike other SARS-CoV-2 variants, the Delta variant can attach to copies of itself, forming larger aggregations, or clumps, of viral particles, suggests a study by scientists at the National Institutes of Health.

11 May 2022

Review portrays clinical journey of messenger RNA vaccines and mRNA-based therapies

Review portrays clinical journey of messenger RNA vaccines and mRNA-based therapies

Researchers reviewed messenger ribonucleic acid (mRNA) technology and highlighted its clinical applications.

11 May 2022

Effectiveness of COVID-19 monoclonal antibodies against SARS-CoV-2 Omicron variant

Effectiveness of COVID-19 monoclonal antibodies against SARS-CoV-2 Omicron variant

Researchers depicted the efficacy of the SARS-CoV-2 monoclonal antibodies (mAbs) against the SARS-CoV-2 Omicron variant.

11 May 2022

Vaccine features that could induce durable humoral immune responses against SARS-CoV-2

Vaccine features that could induce durable humoral immune responses against SARS-CoV-2

A new study explored key vaccine features which could help induce and preserve humoral immunity against SARS-CoV-2 infection.

11 May 2022

Susceptibility of four SARS-CoV-2 Omicron sub-lineages to vaccines and monoclonal antibodies

Susceptibility of four SARS-CoV-2 Omicron sub-lineages to vaccines and monoclonal antibodies

Researchers demonstrated that four SARS-CoV-2 Omicron sub-lineages, BA.1, BA.1.1, BA.2, and BA.3, are resistant to current COVID-19 vaccines and antibody therapeutics to varying extents.

11 May 2022

COVID-19-induced non-cell-autonomous anosmia

COVID-19-induced non-cell-autonomous anosmia

Researchers reported that SARS-CoV-2-induced anosmia was based on non-cell-independent processes.

11 May 2022

Exploring routine saliva testing for SARS-CoV-2 in children

Exploring routine saliva testing for SARS-CoV-2 in children

The focus of a recent study was to implement a weekly SARS-CoV-2 saliva testing schedule in childcare centers.

11 May 2022

New research on excess mortality in the Nordics during COVID

New research on excess mortality in the Nordics during COVID

Both from a scientific and a political standpoint, it is important to record and examine the additional deaths during the ongoing coronavirus disease 2019 (COVID-19) pandemic.

11 May 2022

The 'Big Three' could benefit from the phenomenal strides in vaccine technology

The 'Big Three' could benefit from the phenomenal strides in vaccine technology

Three historically neglected diseases - the 'Big Three', namely tuberculosis, malaria and HIV/AIDS- could be set to benefit from the phenomenal strides that have occurred in vaccine technology in the 2020s.

11 May 2022

Assessment of England's medication prescribing safety during COVID pandemic

Assessment of England's medication prescribing safety during COVID pandemic

In a recent study posted to the medRxiv* preprint server, researchers assessed the impact of coronavirus disease 2019 (COVID-19) on the prescribing safety of high-risk medications on a national scale in England.

11 May 2022

Deep learning reveals genetic determinants of COVID-19-associated mortality

Deep learning reveals genetic determinants of COVID-19-associated mortality

In a recent study posted to the medRxiv* preprint server, researchers applied deep learning methods and identified genetic variants linked to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)-caused mortality.

11 May 2022

COVID-19 and cerebral blood flow

COVID-19 and cerebral blood flow

In a recent study posted to the medRxiv* preprint server, researchers assessed the impact of coronavirus disease 2019 (COVID-19) on cerebral blood flow in infected patients.

10 May 2022

Growing long-COVID health care burden

Growing long-COVID health care burden

In a recent study posted to the medRxiv* preprint server, researchers assessed the long coronavirus disease (COVID) health care burden in Ontario, Canada.

10 May 2022

Pandemic lockdowns have increased women’s water burden

Pandemic lockdowns have increased women’s water burden

Demand for household water increased by as much as a third during pandemic lockdowns, forcing girls and women to spend more time searching for water for families without access to running water, analysis shows.

10 May 2022

Study investigates antibody-mediated response against different SARS-CoV-2 variants

Study investigates antibody-mediated response against different SARS-CoV-2 variants

In a recent study posted to the bioRxiv* preprint server, researchers assessed the impact of coronavirus disease 2019 (COVID-19) on antibody-mediated immunity.

10 May 2022

Decoy ACE2 nanoparticles block the entry of SARS-CoV-2 into cells

Decoy ACE2 nanoparticles block the entry of SARS-CoV-2 into cells

In a recent study posted to the bioRxiv* preprint server, researchers reported that nanoparticles could prevent severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) cell entry.

10 May 2022

Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net.

To start a conversation, please log into your AZoProfile account first, or create a new account.

Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content.

A few things you need to know before we start. Please read and accept to continue.

Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
Large Language Models can make mistakes. Consider checking important information.

I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements.

Please check the box above to proceed.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.